Accepted Manuscript

Title: Notch-out for breast cancer therapies

Authors: Márcia Lamy, Andreia Ferreira, Joana Sales Dias,


Sofia Braga, Gabriela Silva, Ana Barbas

PII: S1871-6784(16)32490-6

DOI: http://dx.doi.org/10.1016/j.nbt.2017.08.004

Reference: NBT 1011

To appear in:



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Notch-Out for Breast Cancer Therapies

Márcia Lamy¹, Andreia Ferreira¹, Joana Sales Dias^{1,2}, Sofia Braga^{3,4}, Gabriela Silva¹, Ana Barbas^{1,5}

¹ iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.

²ITQB, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

³CEDOC, NOVA Medical School, Faculdade de Ciências Médicas Universidade NOVA de Lisboa, Portugal.

⁴Instituto CUF de Oncologia, Lisbon, Portugal

⁵ Bayer Portugal, Carnaxide, Portugal

Corresponding author:

Ana Barbas

iBET - Instituto de Biologia Experimental e Tecnológica

Apartado 12, 2780-901 Oeiras, Portugal

Phone: +351 21 446 94 55

E-mail: ab@ibet.pt

Highlights

- Brief overview of the canonical Notch signaling pathway
- Notch deregulation in disease
- Notch signaling involvement in breast cancer
- Notch pathway targeting in breast cancer as a potential therapy

Abstract

Notch signalling is an evolutionarily highly conserved pathway that plays a crucial role during embryonic development and in tissue homeostasis maintenance during adult life. Abnormal Notch signalling has been implicated in several human genetic disorders and in multiple facets of cancer biology, including stem cell renewal, cancer cell proliferation, tumor angiogenesis and metastasis. Hence, Notch signalling has gained increasing attention as a potential therapeutic target for many disorders. γ-secretase inhibitors (GSIs) were the first therapeutics used to inhibit pathological Notch signalling in various diseases, notably in oncology. Although GSIs show antitumor activity in advanced and metastatic cancer, the lack of substrate specificity and associated toxicity constitute significant limitations to their

Download English Version:

https://daneshyari.com/en/article/4754878

Download Persian Version:

https://daneshyari.com/article/4754878

<u>Daneshyari.com</u>